TSRO Share Price

Open 108.00 Change Price %
High 115.72 1 Day 4.81 4.41
Low 107.50 1 Week 2.01 1.80
Close 113.86 1 Month -10.16 -8.19
Volume 1643726 1 Year 18.83 19.81
52 Week High 192.94
52 Week Low 83.26
TSRO Important Levels
Resistance 2 121.48
Resistance 1 118.34
Pivot 112.36
Support 1 109.38
Support 2 106.24
NASDAQ USA Most Active Stocks
DCTH 0.15 -11.76%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
QQQ 141.23 -0.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.03 50.00%
LOCM 0.09 50.00%
FALC 0.25 38.89%
VRTA 4.50 38.46%
ESMC 0.13 30.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
STXS 0.68 25.93%
OTT 2.39 25.13%
ATRM 1.70 21.43%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
PTSX 0.05 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

TESARO, Inc. (NASDAQ: TSRO)

TSRO Technical Analysis 5
As on 18th Aug 2017 TSRO Share Price closed @ 113.86 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 139.88 & Strong Sell for SHORT-TERM with Stoploss of 132.38 we also expect STOCK to react on Following IMPORTANT LEVELS.
TSRO Target for August
1st Target up-side 143.17
2nd Target up-side 154.03
3rd Target up-side 164.9
1st Target down-side 112.15
2nd Target down-side 101.29
3rd Target down-side 90.42
TSRO Other Details
Segment EQ
Market Capital 430751968.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.tesarobio.com
TSRO Address
TSRO
1000 Winter Street
Suite 3300
Waltham, MA 02451
United States
Phone: 339-970-0900
TSRO Latest News
Interactive Technical Analysis Chart TESARO, Inc. ( TSRO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on TESARO, Inc.
TSRO Business Profile
TESARO, Inc. (TESARO) is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�s marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). TSR-011 is an orally available anaplastic lymphoma kinase (ALK), inhibitor (targeted anti-cancer agent) is in preclinical development.